

CORRECTION

Open Access



# Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Keren Jia<sup>1†</sup>, Yang Chen<sup>1†</sup>, Yu Sun<sup>2</sup>, Yajie Hu<sup>2</sup>, Lei Jiao<sup>3</sup>, Jie Ma<sup>3</sup>, Jiajia Yuan<sup>1</sup>, Changsong Qi<sup>1</sup>, Yanyan Li<sup>1</sup>, Jifang Gong<sup>1</sup>, Jing Gao<sup>4</sup>, Xiaotian Zhang<sup>1</sup>, Jian Li<sup>1</sup>, Cheng Zhang<sup>1\*</sup> and Lin Shen<sup>1\*</sup>

**Correction:** *BMC Medicine* 20, 223 (2022)  
<https://doi.org/10.1186/s12916-022-02421-1>

OS: 23.33 vs.36.6 months,  $P < 0.001$ ; median irOS: 9.27 vs. 12.83 months,  $P = 0.044$ , respectively.”

The original article [1] contains numerical errors in the following sentence regarding median irOS:

‘Additionally, CLDN18.2-positive group had shorter OS and irOS than CLDN18.2-negative group (median OS: 23.33 vs.36.6 months,  $P < 0.001$ ; median irOS: 10.03 vs. 20.13 months,  $P = 0.044$ , respectively).’

The sentence should instead read as follows:

‘Additionally, CLDN18.2-positive group had shorter OS and irOS than CLDN18.2-negative group (median

Published online: 29 September 2023

## Reference

1. Jia K, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. *BMC Medicine*. 2022;20:223. <https://doi.org/10.1186/s12916-022-02421-1>.

<sup>†</sup>Keren Jia and Yang Chen contributed equally.

The original article can be found online at <https://doi.org/10.1186/s12916-022-02421-1>.

\*Correspondence:

Cheng Zhang  
qenya\_z@bjmu.edu.cn  
Lin Shen  
shenlin@bjmu.edu.cn

<sup>1</sup> Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

<sup>2</sup> Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China

<sup>3</sup> Panovue Biotechnology (Beijing) Co, Ltd, Beijing, China

<sup>4</sup> National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

